Study Group: Hematologists and Oncologists in Private Practice (US)(?)
Council Members in this Study Group: 441
Request a survey with this Study Group
Leading Experts in this Study Group
 |
What is a GLG Leader? |
Taral Patel, MDOncologist
Mid Ohio Oncology Hematology Inc.
Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...
Staff Physician
Ironwood Cancer & Research Center
Sujith Kalmadi, MD, is a Staff Physician at the Ironwood Cancer and Research Center in Phoenix, Arizona. Dr. Kalmadi has previously worked as a Clinical Assistant Professor at Baylor school of Medicine in Houston, Texas, and at the Lerner School of Medicine at the Cleveland Clinic, Ohio. He has interest...
Brian Abbott, MDMedical Director of Hematology
Big Sky Oncology
Brian Abbott, MD, is the Medical Director of Hematology at Big Sky Oncology and Sletten Cancer Institute in Great Falls, Montana. His specialties include acute and chronic leukemias (AML, ALL, CML, CLL), all forms of lymphomas including Non-Hodgkin’s and Hodgkin's Lymphoma, myelomas, bone and marrow...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Experts(?)
Avastin is only one of many new targeted therapies that are expensive. It was first introduced in colon cancer and has helped to extend the survival of metastatic colon cancer from 3-6 months to 2 years. It has recently been approved for use in lung and breast cancers as well. It is in these...
The public benefits when new uses are found for old drugs. The benefit comes more quickly as the pharma company does not need to go through as many early studies to allow the approval for the drug use. However, I believe that pharma realizes that new uses for old drugs is not the way...
Use of Epo Stimulating Agents (ESAs) for cancer patients have all but come to a screeching halt when a plattoon of studies came out suggesting that ESAs might actually cause more harm, notably by possibly acting as a growth factor for tumor cells. Now, reserachers are trying to determine...
Transgene's TG4010 vaccine has a fairy elegant two-gene design. It appears to add benefit to a standard chemo regimen in this good-sized, randomized Phase II study for advanced lung cancer. More mature survival data will be ready by year's end. Phase III study is being planned. ...
Adding novel biologic agents (such as ASA404) to traditional chemotherapy is a very hot trend in cancer research. The data from Antisoma's lung cancer study are certainly intriguing, but again, phase II, and retrospective.
Most Common Company Types:
- Office Based Private Practice or Clinic
- Academic Medical Center/Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Owner
- Partner
- President
- Physician - Director
- Director
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms